Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
1.400
+0.180 (14.75%)
At close: Nov 21, 2025, 4:00 PM EST
1.445
+0.045 (3.19%)
After-hours: Nov 21, 2025, 7:59 PM EST
Ovid Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Ovid Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $3.50, which forecasts a 150.00% increase in the stock price over the next year. The lowest target is $1.50 and the highest is $5.00.
Price Target: $3.50 (+150.00%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ovid Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Initiates $5 | Buy | Initiates | $5 | +257.14% | Nov 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $2 → $1.5 | Strong Buy | Maintains | $2 → $1.5 | +7.14% | May 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3 → $2 | Strong Buy | Maintains | $3 → $2 | +42.86% | Mar 24, 2025 |
| BTIG | BTIG | Strong Buy Maintains $5 → $4 | Strong Buy | Maintains | $5 → $4 | +185.71% | Mar 24, 2025 |
| Wedbush | Wedbush | Buy Maintains $4 → $3 | Buy | Maintains | $4 → $3 | +114.29% | Mar 12, 2025 |
Financial Forecast
Revenue This Year
6.69M
from 566.00K
Increased by 1,081.80%
Revenue Next Year
209.10K
from 6.69M
Decreased by -96.87%
EPS This Year
-0.47
from -0.37
EPS Next Year
-0.42
from -0.47
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.5M | 735,000 | |||
| Avg | 6.7M | 209,100 | |||
| Low | 6.3M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1,217.5% | -89.0% | |||
| Avg | 1,081.8% | -96.9% | |||
| Low | 1,008.1% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.38 | -0.23 | |||
| Avg | -0.47 | -0.42 | |||
| Low | -0.56 | -0.64 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.